Patents by Inventor Christopher Neil Farthing

Christopher Neil Farthing has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9079914
    Abstract: A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.
    Type: Grant
    Filed: July 21, 2010
    Date of Patent: July 14, 2015
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: John Mark Ellard, Christopher Neil Farthing, Adrian Hall
  • Patent number: 8940734
    Abstract: The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein X is hydrogen or fluorine; A is CH or N; Y is methyl, ethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, difluoroethyl, methoxy, ethoxy, methoxymethyl or —C?N; and pharmaceutically acceptable salts thereof; which compound has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: January 27, 2015
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Adrian Hall, Christopher Neil Farthing, Jose Luis Castro Pineiro
  • Publication number: 20140142091
    Abstract: The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein X is hydrogen or fluorine; A is CH or N; Y is methyl, ethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, difluoroethyl, methoxy, ethoxy, methoxymethyl or —C?N; and pharmaceutically acceptable salts thereof; which compound has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.
    Type: Application
    Filed: October 18, 2013
    Publication date: May 22, 2014
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Adrian Hall, Christopher Neil Farthing, Jose Luis Castro Pineiro
  • Patent number: 8592408
    Abstract: The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein X is hydrogen or fluorine; A is CH or N; Y is methyl, ethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, difluoroethyl, methoxy, ethoxy, methoxymethyl or —C?N; and pharmaceutically acceptable salts thereof; which compound has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.
    Type: Grant
    Filed: November 26, 2012
    Date of Patent: November 26, 2013
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Adrian Hall, Christopher Neil Farthing
  • Patent number: 8338407
    Abstract: The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein X is hydrogen or fluorine; A is CH or N; Y is methyl, ethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, difluoroethyl, methoxy, ethoxy, methoxymethyl or —C?N; and pharmaceutically acceptable salts thereof; which compound has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: December 25, 2012
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Adrian Hall, Christopher Neil Farthing
  • Publication number: 20120202804
    Abstract: A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.
    Type: Application
    Filed: July 21, 2010
    Publication date: August 9, 2012
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: John Mark Ellard, Christopher Neil Farthing, Adrian Hall
  • Publication number: 20120190672
    Abstract: The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein X is hydrogen or fluorine; A is CH or N; Y is methyl, ethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, difluoroethyl, methoxy, ethoxy, methoxymethyl or —C?N; and pharmaceutically acceptable salts thereof; which compound has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.
    Type: Application
    Filed: January 20, 2012
    Publication date: July 26, 2012
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Adrian Hall, Christopher Neil Farthing, Jose Luis Castro Pineiro
  • Patent number: 8178552
    Abstract: The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof, the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and the use in medicine and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and/or and autoimmune diseases. The invention also provides processes for the manufacture of said compounds of formula (I) or a pharmaceutically acceptable salt thereof and compositions containing them.
    Type: Grant
    Filed: August 5, 2009
    Date of Patent: May 15, 2012
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Piotr Pawel Graczyk, Paschalis Dimopoulos, Afzal Khan, Gurpreet Singh Bhatia, Christopher Neil Farthing
  • Patent number: 7951802
    Abstract: The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and/or and autoimmune diseases. The invention also provides processes for the manufacture of compounds of formula (I) or a pharmaceutically acceptable salt thereof and compositions containing them.
    Type: Grant
    Filed: August 5, 2009
    Date of Patent: May 31, 2011
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Piotr Pawel Graczyk, Paschalis Dimopoulos, Christopher Neil Farthing, Gurpreet Singh Bhatia, Afzal Khan
  • Publication number: 20100069354
    Abstract: The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof, the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and the use in medicine and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and/or and autoimmune diseases. The invention also provides processes for the manufacture of said compounds of formula (I) or a pharmaceutically acceptable salt thereof and compositions containing them.
    Type: Application
    Filed: August 5, 2009
    Publication date: March 18, 2010
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Piotr Pawel GRACZYK, Paschalis DIMOPOULOS, Afzal KHAN, Gurpreet Singh BHATIA, Christopher Neil FARTHING
  • Publication number: 20100069358
    Abstract: The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and/or and autoimmune diseases. The invention also provides processes for the manufacture of said compounds of formula (I) or a pharmaceutically acceptable salt thereof and compositions containing them.
    Type: Application
    Filed: August 5, 2009
    Publication date: March 18, 2010
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Piotr Pawel GRACZYK, Paschalis DIMOPOULOS, Christopher Neil FARTHING, Gurpreet Singh BHATIA, Afzal KHAN
  • Patent number: 7381734
    Abstract: Compounds of formula (I) where R5, R6a, each X, L, Cy and Lp are as defined in the specification, are tryptase inhibitors useful as antiinflammatory agents.
    Type: Grant
    Filed: July 22, 2005
    Date of Patent: June 3, 2008
    Assignee: Tularik Limited
    Inventors: Sarah Elizabeth Lively, Bohdan Waszkowycz, Martin James Harrison, Christopher Neil Farthing, Keith Michael Johnson
  • Patent number: 7157585
    Abstract: Compounds of formula (I) where R5, R6a, each X, L, Cy and Lp are as defined in the specification, are tryptase inhibitors useful as antiinflammatory agents.
    Type: Grant
    Filed: May 11, 2005
    Date of Patent: January 2, 2007
    Assignee: Tularik Limited
    Inventors: Sarah Elizabeth Lively, Bohdan Waszkowycz, Martin James Harrison, Christopher Neil Farthing, Keith Michael Johnson
  • Patent number: 7074934
    Abstract: Compounds of formula (I) where R2, each X, L, Y, Cy, Lp, D and n are as defined in the specification, are serine protease inhibitors useful as antithrombotic agents.
    Type: Grant
    Filed: June 12, 2001
    Date of Patent: July 11, 2006
    Assignee: Tularik Limited
    Inventors: Sarah Elizabeth Lively, Bohdan Waszkowycz, Martin James Harrison, Christopher Neil Farthing, Keith Michael Johnson
  • Patent number: 7067516
    Abstract: Compounds of formula (I) where R5, R6a, each X, L, Cy and Lp are as defined in the specification, are tryptase inhibitors useful as antiinflammatory agents.
    Type: Grant
    Filed: December 12, 2001
    Date of Patent: June 27, 2006
    Assignee: Tularik Limited
    Inventors: Sarah Elizabeth Lively, Martin James Harrison, Neil Jason Naylor, Christopher Neil Farthing, Bohdan Waszkowycz
  • Patent number: 6916957
    Abstract: Compounds of formula (I) where R5, R6a, each X, L, Cy and Lp are as defined in the specification, are tryptase inhibitors useful as antiinflammatory agents.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: July 12, 2005
    Assignee: Tularik Limited
    Inventors: Sarah Elizabeth Lively, Bohdan Waszkowycz, Martin James Harrison, Christopher Neil Farthing, Keith Michael Johnson
  • Publication number: 20040116439
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: June 2, 2003
    Publication date: June 17, 2004
    Inventors: Sarah Elizabeth Lively, Martin James Harrison, Neil Jason Naylor, Christopher Neil Farthing, Bohdan Waszkowycz
  • Publication number: 20030216403
    Abstract: 1
    Type: Application
    Filed: May 14, 2003
    Publication date: November 20, 2003
    Inventors: Sarah Elizabeth Lively, Bohdan Waszkowycz, Martin James Harrison, Christopher Neil Farthing, Keith Michael Johnson
  • Publication number: 20030018059
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: June 3, 2002
    Publication date: January 23, 2003
    Inventors: Sarah Elizabeth Lively, Bohdan Waszkowycz, Martin JAMES Harrison, Christopher Neil Farthing, Keith Michael Johnson